Literature DB >> 21291478

Potential pathophysiological mechanisms in osteonecrosis of the jaw.

Regina Landesberg1, Victoria Woo, Serge Cremers, Matthew Cozin, Darja Marolt, Gordana Vunjak-Novakovic, Stavroula Kousteni, Srikala Raghavan.   

Abstract

Bisphosphonates are used in the treatment of hypercalcemia of malignancy, skeletal complications associated with metastastic bone disease, Paget's disease, and osteoporosis. Osteonecrosis of the jaw (ONJ) is a recently described clinical condition that has been associated with the use of nitrogen-containing bisphosphonates. Reports describing this entity first appeared in the literature in 2003. While there have been significant numbers of case reports and a limited number of retrospective and prospective studies examining risk factors associated with ONJ, the pathophysiology of this condition remains elusive. In this review, we explore proposed mechanisms underlying ONJ development and identify potential areas for future investigation.
© 2011 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21291478      PMCID: PMC4477826          DOI: 10.1111/j.1749-6632.2010.05835.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  101 in total

1.  Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.

Authors:  Daniele Santini; Bruno Vincenzi; Sara Galluzzo; Fabrizio Battistoni; Laura Rocci; Olga Venditti; Gaia Schiavon; Silvia Angeletti; Federica Uzzalli; Michele Caraglia; Giordano Dicuonzo; Giuseppe Tonini
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

2.  Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.

Authors:  Salvatore L Ruggiero; John Fantasia; Eric Carlson
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2006-07-31

3.  Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?

Authors:  M Ardine; D Generali; M Donadio; S Bonardi; M Scoletta; A M Vandone; M Mozzati; O Bertetto; A Bottini; L Dogliotti; A Berruti
Journal:  Ann Oncol       Date:  2006-03-08       Impact factor: 32.976

4.  Pamidronate induces modifications of circulating angiogenetic factors in cancer patients.

Authors:  Daniele Santini; Bruno Vincenzi; Giuseppe Avvisati; Giordano Dicuonzo; Fabrizio Battistoni; Michele Gavasci; Alfredo Salerno; Vincenzo Denaro; Giuseppe Tonini
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

5.  Development of the osteoblast phenotype in primary human osteoblasts in culture: comparison with rat calvarial cells in osteoblast differentiation.

Authors:  H Siggelkow; K Rebenstorff; W Kurre; C Niedhart; I Engel; H Schulz; M J Atkinson; M Hüfner
Journal:  J Cell Biochem       Date:  1999-10-01       Impact factor: 4.429

6.  Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study.

Authors:  Roland D Chapurlat; Monique Arlot; Brigitte Burt-Pichat; Pascale Chavassieux; Jean Paul Roux; Nathalie Portero-Muzy; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

7.  Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.

Authors:  Daniele Santini; Bruno Vincenzi; Giordano Dicuonzo; Giuseppe Avvisati; Cristian Massacesi; Fabrizio Battistoni; Michele Gavasci; Laura Rocci; Maria Cristina Tirindelli; Vittorio Altomare; Massimo Tocchini; Maurizio Bonsignori; Giuseppe Tonini
Journal:  Clin Cancer Res       Date:  2003-08-01       Impact factor: 12.531

8.  Hypofibrinolysis: a common, major cause of osteonecrosis.

Authors:  C J Glueck; R Freiberg; H I Glueck; C Henderson; M Welch; T Tracy; D Stroop; T Hamer; F Sosa; M Levy
Journal:  Am J Hematol       Date:  1994-02       Impact factor: 10.047

9.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

10.  The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins.

Authors:  R E Hewitt; A Lissina; A E Green; E S Slay; D A Price; A K Sewell
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

View more
  48 in total

Review 1.  Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease.

Authors:  Peter K Wong; Gelsomina L Borromeo; John D Wark
Journal:  Rheumatol Int       Date:  2013-05-08       Impact factor: 2.631

2.  Novel therapy to reverse the cellular effects of bisphosphonates on primary human oral fibroblasts.

Authors:  Matthew Cozin; Bradley M Pinker; Kimberley Solemani; Jeremy M Zuniga; Stephen C Dadaian; Serge Cremers; Regina Landesberg; Srikala Raghavan
Journal:  J Oral Maxillofac Surg       Date:  2011-07-31       Impact factor: 1.895

3.  Bisphosphonate uptake in areas of tooth extraction or periapical disease.

Authors:  Simon Cheong; Shuting Sun; Benjamin Kang; Olga Bezouglaia; David Elashoff; Charles E McKenna; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Oral Maxillofac Surg       Date:  2014-07-12       Impact factor: 1.895

4.  Rescue bisphosphonate treatment of alveolar bone improves extraction socket healing and reduces osteonecrosis in zoledronate-treated mice.

Authors:  Akishige Hokugo; Keiichi Kanayama; Shuting Sun; Kenzo Morinaga; Yujie Sun; QingQing Wu; Hodaka Sasaki; Hiroko Okawa; Courtney Evans; Frank H Ebetino; Mark W Lundy; Keivan Sadrerafi; Charles E McKenna; Ichiro Nishimura
Journal:  Bone       Date:  2019-03-26       Impact factor: 4.398

5.  RANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease.

Authors:  Tara L Aghaloo; Simon Cheong; Olga Bezouglaia; Paul Kostenuik; Elisa Atti; Sarah M Dry; Flavia Q Pirih; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2014-04       Impact factor: 6.741

6.  Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model.

Authors:  Rafael Scaf de Molon; Simon Cheong; Olga Bezouglaia; Sarah M Dry; Flavia Pirih; Joni Augusto Cirelli; Tara L Aghaloo; Sotirios Tetradis
Journal:  Bone       Date:  2014-08-02       Impact factor: 4.398

7.  Osteo-radio-necrosis (ORN) and bisphosphonate-related osteonecrosis of the jaws (BRONJ): the histopathological differences under the clinical similarities.

Authors:  Konstantinos T Mitsimponas; Patrick Moebius; Kerstin Amann; Philipp Stockmann; Karl-Andreas Schlegel; Friedrich-Wilhelm Neukam; Falk Wehrhan
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

8.  Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice.

Authors:  Ben Kang; Simon Cheong; Thawinee Chaichanasakul; Olga Bezouglaia; Elisa Atti; Sarah M Dry; Flavia Q Pirih; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2013-07       Impact factor: 6.741

9.  Low-level laser therapy for osteonecrotic lesions: effects on osteoblasts treated with zoledronic acid.

Authors:  Fernanda Gonçalves Basso; Ana Paula Silveira Turrioni; Diana Gabiela Soares; Vanderlei Salvador Bagnato; Josimeri Hebling; Carlos Alberto de Souza Costa
Journal:  Support Care Cancer       Date:  2014-05-07       Impact factor: 3.603

Review 10.  Chemical and Radiation-Associated Jaw Lesions.

Authors:  Temitope T Omolehinwa; Sunday O Akintoye
Journal:  Dent Clin North Am       Date:  2016-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.